不同剂量达沙替尼对慢性粒细胞白血病疗效的META技术分析.docx

不同剂量达沙替尼对慢性粒细胞白血病疗效的Meta分析 慢性粒细胞白血病(chronic myeloid leukemia，CML)是骨髓造血干细胞克隆性增殖形成的恶性肿瘤，占成人白血病的15％，全球年发病率为1.6-2.0/10万 HYPERLINK \l _ENREF_1 \o OBrien, 2009 #62  ADDIN EN.CITE  ADDIN EN.CITE.DATA 1。我国1986至1988年在22个省(市、自治区)46个调查点进行白血病发病情况调查显示CML的年发病率为0.36/10万。CML特征是带有9号和22号染色体易位的造血干细胞克隆性扩增，这种染色体易位称为费城染色体(Ph)。t(9；22)导致BCR-ABL融合基因的产生，该融合基因产生融合蛋白p210BCR-ABL。P210蛋白具有极强的酪氨酸激酶活性，使一系列信号蛋白发生持续性磷酸化，影响细胞的增殖分化、凋亡及黏附，从而导致CML发生 HYPERLINK \l _ENREF_1 \o OBrien, 2009 #62  ADDIN EN.CITE  ADDIN EN.CITE.DATA 1。 酪氨酸激酶抑制剂(tyrosine kinase inhibitor，TKI)为治疗CML的靶向药物，可阻断ATP位点，选择性抑制p120蛋白的酪氨酸激酶活性，抑制细胞增殖并诱导其凋亡 HYPERLINK \l _ENREF_2 \o Balabanov, 2014 #63  ADDIN EN.CITE EndNoteCiteAuthorBalabanov/AuthorYear2014/YearRecNum63/RecNumDisplayTextstyle face=superscript2/style/DisplayTextrecordrec-number63/rec-numberforeign-keyskey app=EN db-id=fs25zvaaqs9p9xefd24vprvk2dzf5twrrxtd63/key/foreign-keysref-type name=Journal Article17/ref-typecontributorsauthorsauthorBalabanov, S./authorauthorBraig, M./authorauthorBrummendorf, T. H./author/authors/contributorstitlestitleCurrent aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia/titlesecondary-titleDrug Discov Today Technol/secondary-titlealt-titleDrug discovery today. Technologies/alt-title/titlesperiodicalfull-titleDrug Discov Today Technol/full-titleabbr-1Drug discovery today. Technologies/abbr-1/periodicalalt-periodicalfull-titleDrug Discov Today Technol/full-titleabbr-1Drug discovery today. Technologies/abbr-1/alt-periodicalpages89-99/pagesvolume11/volumekeywordskeywordAntineoplastic Agents/*therapeutic use/keywordkeyword*Drug Resistance, Neoplasm/keywordkeywordHumans/keywordkeywordLeukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy/keywordkeywordProtein Kinase Inhibitors/*therapeutic use/keyword/keywordsdatesyear2014/yearpub-datesdateMar/date/pub-dates/datesisbn1740-6749 (Electronic)#xD;1740-6749 (Linking)/isbnaccession-nuaccession-numurlsrelated-urlsurl/pubmedurl/